Skip to main content

Rachel Irving Pitts

Associate

[email protected]

+1.617.348.4454

Follow:
Share:

Rachel's practice primarily involves transactional and regulatory matters, including mergers and acquisitions, regulatory compliance review, telemedicine issues, and provider and service contracting matters for various health care providers, administrative organizations, payors, and health systems. She works with hospital systems, dialysis, long-term care, and retail providers, individual providers and practice groups, management companies, independent practice associations, and third-party administrators and payors.

Rachel has represented a variety of pro bono clients at the firm, including counseling a small business through start-up, advocating for a tenant in housing court, and successfully arguing for a client’s Social Security Disability Insurance benefits.

Prior to joining Mintz, Rachel was a law clerk for the Illinois Attorney General and worked for the Massachusetts Medical Society in its Membership and Legal Departments. While a student prosecutor at Boston University School of Law, she successfully briefed and argued against a motion to suppress evidence in a criminal hearing.

Education

  • Boston University School of Law (JD)
  • University of Illinois - Urbana-Champaign (BS)

Involvement

  • Member, Massachusetts Bar Association
  • Member, Boston Bar Association
  • Member, American Health Lawyers Association
  • Executive Board, Boston University Law Young Alumni Council
  • Vice Chair, BHCHP Emerging Leaders Board
  • Member, 2011 – 2012 Women’s Leadership Program, Greater Boston Chamber of Commerce

Viewpoints

Viewpoint
Our ML Strategies colleague Aaron Josephson was quoted extensively in an August 16 FDA Week article (FDA Week is a focused newsletter from InsideHealthPolicy) covering the debate over FDA’s withdrawal of its proposed rule on reporting data falsification. Aaron spent over a decade working at the FDA, and reviewed the rule when he was working as a senior policy advisor in FDA’s device center in 2017. The rule was proposed back in 2010, and FDA withdrew the regulation last fall after determining it would not protect research subjects or improve the quality of research data submitted to FDA. The debate over this regulatory proposal has resurfaced in recent weeks, following the agency’s announcement that it had learned of a data manipulation issue with animal testing contained in the package submitted for a newly approved gene therapy product called Zolgensma.
Viewpoint General
Mintz/ML Strategies’ 4th Annual Pharmacy & Pharmaceutical Industry Summit has been scheduled for Thursday, May 2, 2019 – mark your calendars! People from across the industry will gather for one day to share insights about issues that the players in this complex marketplace are tackling.
Viewpoint General

Massachusetts HPC Health Care Cost Trends Hearing: Key Takeaways

October 24, 2018 | Blog | By Daria Niewenhous, Caitlin Beresin, Rachel Irving Pitts, Cassandra Paolillo

The Massachusetts Health Policy Commission (“HPC”) held its annual Health Care Cost Trends Hearing on October 16-17, 2018. The hearing covered a wide range of topics affecting the health care industry here in the Commonwealth and across the country. Here are some key takeaways and a legislative outlook.

Join us July 12th - Webinar on Qui Tam Relators

June 26, 2017 | Blog | By Rachel Irving Pitts

Whistleblowers remain a steady source of False Claim Act (FCA) suits against health care and life science companies each year.  Join our upcoming webinar - “Qui Tam Relators: What You Need to Know” on July 12 at 1pm ET.

Health Care Weekly Preview from ML Strategies - Week of May 22, 2017

May 23, 2017 | Blog | By Rachel Irving Pitts

Our ML Strategies colleagues have published a preview for another big week in health care. The American Health Care Act (AHCA) continues to be a big story as the Senate works on its version. This week we watch for updates on these items and how they might impact AHCA discussions.

Massachusetts Budget Process Continues with Impact on Health Care

April 20, 2017 | Blog | By Rachel Irving Pitts

Next week, the Massachusetts House will continue the budget process and debate over 1000 amendments that members filed to the House Ways and Means Committee’s proposed $40.3 billion FY2018 budget.

Changes Needed to Stark Law Advisory Opinion Process

March 29, 2017 | Blog | By Rachel Irving Pitts

The Stark Law has caused angst for many a physician and many a health care lawyer over the years. The Stark Law has also troubled hospital and health system CEOs looking for ways to align incentives with physicians. Some stakeholders say Congress should do away with the myriad statutes and regulations that comprise the strict liability federal law banning physician self-referral.

Massachusetts Health Care Industry Facing Policy Changes

February 23, 2017 | Blog | By Rachel Irving Pitts

The Massachusetts health care industry is facing policy changes from state and federal decision makers. In a recent Alert, my ML Strategies colleagues Julie Cox, Steven Baddour, Dan Connelly, Caitlin Beresin and Max Fathy consider how state and federal government action will affect a wide variety of health care stakeholders.

Health Care Outlook for 2017 from ML Strategies

January 23, 2017 | Blog | By Rachel Irving Pitts

ML Strategies has published its Washington Outlook for 2017, with a collection of materials covering what to expect from the 115th Congress, spanning multiple issues and industries.

21st Century Cures Act – Med Tech Impact Webinar January 18

December 21, 2016 | Blog | By Rachel Irving Pitts

As you have seen in our recent coverage, the 21st Century Cures Act is a major legislative undertaking, and it will have a great impact the medical device industry. Join my Mintz Levin and ML Strategies colleagues Tom Crane, Bethany Hills, and Rodney Whitlock on January 18th for a MassMEDIC webinar, “Impact of the Cures Act on the Medical Device Industry.”